Louis Levy, MBA, began his career with Cepton, a strategy consulting boutique for French mid-size biotechs, where he worked on pharmaceutical development, European commercial launches, and R&D organizations. He was involved in notable licensing transactions in allergy immunotherapy (Stallergenes-Shionogi) and hemophilia (Ipsen-Inspiration Biopharm). As a Blavatnik Fellow in 2015, he worked on the DNA-PAINT technology and investigated the biotech entrepreneurship trends in NYC. Since then, he has joined Ultivue, the startup formed out of DNA-PAINT, to spearhead corporate and business development functions. He is a graduate of the French grande école Telecom Bretagne, with a master’s degree in engineering.
Vicki Sato, PhD, leads the Blavatnik Fellowship in Life Science Entrepreneurship started in 2014 at Harvard Business School. Dr. Sato was appointed Professor of Management Practice at Harvard Business School in 2006. Prior to that, she had been the President of Vertex Pharmaceuticals from 2000 until her retirement from that position in 2005, and had previously served eight years as Vertex’s chief scientific officer and chair of the scientific advisory board. Prior to joining Vertex in 1992, she was with Biogen from 1984 to 1992, most recently as vice president of research and a member of the scientific advisory board. Today, Dr. Sato is also a business advisor to various enterprises in the biotechnology and pharmaceutical industries.
Marc Tessier-Lavigne was the first Rockefeller University president to come from industry when he left a top job at Genentech in 2011 to move on to Manhattan’s East Side. In his... Read more »
June 13, 2019
© 2007-2019, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.